Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
about
Advances and challenges in the management of complement-mediated thrombotic microangiopathiesFever, Jaundice, Abdominal Pain, Skin Lesions, and Dark Urine for 2 Days.Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan.First-Line, Early and Long-Term Eculizumab Therapy in Atypical Hemolytic Uremic Syndrome: A Case Series in Pediatric Patients.Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship.Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case ReportTurkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patientsThrombotic microangiopathy: expanding genetic, clinical and therapeutic spectra and the need for worldwide implementation of recent advancesSelectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States.Averting the legacy of kidney disease: Focus on childhood.[In time: averting the legacy of kidney disease - focus on childhood].Averting the legacy of kidney disease - focus on childhood.Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.The bittersweet taste of tubulo-interstitial glycans.Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab.Averting the Legacy of Kidney Disease - Focus on Childhood.Averting the legacy of kidney disease: focus on childhood.Averting the legacy of kidney disease - focus on childhood.Averting the Legacy of Kidney Disease-Focus on Childhood.Averting the Legacy of Kidney Disease--Focus on Childhood.Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.Averting the Legacy of Kidney Disease: Focus on Childhood.Averting the legacy of kidney disease: focus on childhoodWorld Kidney Day 2016: Averting the legacy of kidney disease—focus on childhoodAverting the legacy of kidney disease: focus on childhood
P2860
Q26796453-C26930B3-1EA3-46A6-B3F1-AD2182BAA63DQ33423489-909956E1-1849-45F8-8D16-853B99F06D9AQ33424274-DE571E54-D4ED-49EA-9227-C9BE68E7F683Q33435451-A4EC1602-53FC-40BA-9D04-61F134CC95EFQ33441880-ABE7FCDF-CD4D-4E1E-965D-6B90F2D1458FQ33442695-E72650C6-0B45-4633-9EFD-1E94BDC1B725Q36241014-1BCE9793-83BE-4209-91BD-B796FDD1D668Q36306802-F3AC53F4-C745-4D3B-9A54-873373BFC06AQ36563619-98E91994-B056-4D6A-B14D-D0AF61907C41Q36641955-C269DF28-FBCB-4961-9214-BBCDB97A8376Q36696530-5862F92F-9CD5-4262-938A-6AFFFA10BD7BQ36697391-10129CA5-D630-4962-B7C7-A244599B1F3DQ36830884-8BE8327B-E327-4A01-9D82-37AC4191344FQ38867819-34E6BD63-8BB4-40E8-A242-37996FBEAF7AQ38907049-B11C829B-F3A4-42C6-9185-A3D8309589D5Q39240506-A5FD612E-1B67-49BE-8D12-BC447A76915DQ40593336-0477E7FD-8AFB-4397-A8FA-2DCBC8A97A71Q40617280-CEBF40F7-8C5D-41EE-80B8-F312DC513F3BQ40891508-0A9F4F22-8554-4A44-A034-252B3D2916FFQ41931984-99D8EF69-37A7-471A-9395-BB42A9D57EC6Q42430577-A01ED8D9-E692-498C-B9C3-A59F127C7404Q42750457-5AB94476-A3CE-45C8-81B2-37CC07958511Q47129863-14BC233E-B997-4FAE-BEFE-402C4B73271CQ54841089-90387589-6894-4BCC-AEDA-AF40F03CEC49Q57771439-A7753866-7E1A-47D9-8319-FD449092598AQ57771463-65F145EB-1C55-4129-8D6E-11F2E8A17F42Q57771473-E24AAA5C-0DDC-4964-A93B-78740BAA18E0
P2860
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@ast
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@en
type
label
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@ast
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@en
prefLabel
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@ast
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@en
P2093
P2860
P356
P1476
Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
@en
P2093
Jack F M Wetzels
Jacobien C Verhave
Nicole C A J van de Kar
P2860
P304
P356
10.1093/NDT/GFU235
P407
P478
29 Suppl 4
P577
2014-09-01T00:00:00Z